A study on cisplatin -paclitaxel induced peripheral neuropathy in cancer patients

Umamaheshwari C., Shanthi M., Malathi M.
2019 International Journal of Basic & Clinical Pharmacology  
Chemotherapy induced peripheral neuropathy is a significant disability after the treatment of large number of cancers and they have an impact on quality of life. The aim of the present endeavour was to study the cisplatin-paclitaxel induced peripheral neuropathy in patients with lung or ovarian cancerMethods: The study was carried out in the Department of Oncology, Government Rajaji Hospital, Madurai, after obtaining clearance from Institutional ethical committee, Government Rajaji Hospital,
more » ... urai. Thirty newly diagnosed patients suffering from Lung or ovarian cancer attending Oncology department were selected. After satisfying inclusion and exclusion criteria. Patient received injection cisplatin 60 mg/m2 and injection paclitaxel 175 mg/m2. Nerve conduction study was done to assess the peripheral neuropathy. It was done before starting the chemotherapy. Patients with grade 0 neuropathy were included for the study. Nerve conduction study was repeated after each cycle. The time taken to develop peripheral neuropathy was assessed using Cancer Institute - Common Toxicity Criteria version 3.0. The data were analyzed with SPSS statistical software package (Version 16.0 SPSS Inc., Chicago, USA ).Results: There is a statistically significant reduction in sensory nerve (sural) amplitude (SNAP) and latency (p <0.05) indicating significant axonal damage. The time taken to develop peripheral neuropathy was 3 cycles with grade 3/4.Conclusions: In this present study, the neurotoxicity induced by cisplatin-paclitaxel in patients with lung or ovarian carcinoma was observed, so that early intervention can prevent the permanent neurotoxicity.
doi:10.18203/2319-2003.ijbcp20191587 fatcat:foclcb3hqbhdnhi3oxklnriylu